High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.

Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

Original Publication: Oxford ; New York : Pergamon Press

Antigens, CD34/*biosynthesis ; Megakaryocytes/*metabolism ; Myelodysplastic Syndromes/*metabolism; Adult ; Aged ; Aged, 80 and over ; Biopsy ; Bone Marrow/metabolism ; Bone Marrow/pathology ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Male ; Megakaryocytes/pathology ; Middle Aged ; Multivariate Analysis ; Myelodysplastic Syndromes/pathology ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models

Expression of CD34 on mature-appearing megakaryocytes can be seen in various intrinsic bone marrow (BM) disorders as well as reactive bone marrows. In this study we investigate the clinical significance of CD34+ megakaryocytes in myelodysplastic syndromes (MDSs). Expression of CD34 on megakaryocytes was assessed on BM biopsies obtained from 202 patients with MDS. High-level (≥20%) CD34 expression on megakaryocytes was found in BM of 29 patients (14%). The expression of CD34 on megakaryocytes is correlated with severe cytopenia, higher numbers of myeloblasts, more frequent and higher risk cytogenetic abnormalities, and a shorter overall survival. Multivariate analysis indicated that the expression of CD34 on megakaryocytes could be a strong and an independent poor prognostic factor in MDS, with a hazard ratio of 2.53.
(Published by Elsevier Ltd.)

0 (Antigens, CD34)

Date Created: 20110304 Date Completed: 20111207 Latest Revision: 20191210

20240829

10.1016/j.leukres.2011.01.009

21367453